GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTAW) » Definitions » Short Interest

Pasithea Therapeutics (Pasithea Therapeutics) Short Interest


View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Pasithea Therapeutics's Short Interest

For the Biotechnology subindustry, Pasithea Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pasithea Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's Short Interest falls into.



Pasithea Therapeutics (Pasithea Therapeutics) Business Description

Traded in Other Exchanges
Address
1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.

Pasithea Therapeutics (Pasithea Therapeutics) Headlines

From GuruFocus

Majority of Stockholders Support Pasithea Directors at Special Meeting

By GlobeNewswire GlobeNewswire 12-14-2022